This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
by Zacks Equity Research
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
by Zacks Equity Research
ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.
Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 0% and 5.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
by Zacks Equity Research
EXEL tops on earnings and sales in the third quarter as lead drug Cabometyx maintains momentum. The company also raises its revenue guidance for 2024.
Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seeking Clues to Alnylam (ALNY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alnylam (ALNY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of -6.41% and 2.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Starboard Slams Pfizer for R&D Inefficiencies, Overpaid Acquisitions
by Zacks Equity Research
Starboard calls out PFE's board of directors to take action against the latter's management for not earning sustainable revenue returns on R&D and M&A.
Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Gilead, MRK Report Data From Investigational Combination Study for HIV
by Zacks Equity Research
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B
by Zacks Equity Research
The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
by Zacks Equity Research
Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
by Zacks Equity Research
The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
by Zacks Equity Research
With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating advanced Parkinson's disease.
Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year?
by Zacks Equity Research
Here is how Alnylam Pharmaceuticals (ALNY) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU
by Zacks Equity Research
ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR amyloidosis with cardiomyopathy.
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
by Zacks Equity Research
The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise.
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
by Zacks Equity Research
MeiraGTx stock rises 15% as gene therapy candidate betters sham treatment in Parkinson's disease patients.
JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study
by Zacks Equity Research
Data from a late-stage study showed that Jazz's Zepzelca, combined with Roche's Tecentriq, improved survival rates in certain patients with small-cell lung cancer.
Exelixis Gets Favorable Ruling in Patent Litigation With MSN
by Zacks Equity Research
The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises
by Zacks Equity Research
Vanda's board of directors unanimously rejects the second takeover proposal from Cycle Group Holdings. Shares rise on the news.
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
by Zacks Equity Research
LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug
by Zacks Equity Research
Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.